← Eichor
Study identifier: NCT07439965 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions

Condition: Subarachnoid Aneurysm Hemorrhage · Unruptured Intracranial Aneurysm  ·  Sponsor: The First Hospital of Jilin University

PhaseN/A
Planned participants120
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

The goal of this observational study is to learn about the protein heterogeneity in extracellular vesicles (EVs) derived from different human blood circulatory regions of patients with ruptured or unruptured intracranial aneurysms. The main objectives are: Reveal the proteomic heterogeneity of EVs in different blood circulatory regions of the human body。 Reveal the proteomic differences of EVs in cerebral feeding arteries and draining veins between patients with aneurysmal subarachnoid hemorrhage and those without hemorrhage. Explore EV-derived protein biomarkers that reflect the diagnosis and prognosis of subarachnoid hemorrhage

This description comes directly from the study's public registry record.

Talk to the study team

Zheng Wan, Medical Doctor, MD  ·  86-18743059601  ·  wanzheng@jlu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

First Hospital of Jilin UniversityChangchun, Jilin, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07439965